// App-Quantinova.ai

PB2171 : Effectiveness and Safety of Rivaroxaban in Patients with Cancer-associated Venous Thromboembolism

Researchers

Presenter

  • O.S. Costa

Principal Investigators

  • C.G. Kohn

  • G.H. Lyman

  • N.M. Kuderer

  • T.J. Bunz

  • C.I. Coleman

Medical Centers

  • University of Connecticut School of Pharmacy, Department of Pharmacy Practice, Storrs, United States

  • Hartford Hospital, Evidence Based Practice Center, Hartford, United States

  • University of Connecticut School of Pharmacy, Department of Pharmacy Practice, Storrs, United States

  • Fred Hutchinson Cancer Research Center and University of Washington, Public Health Science Division, Seattle, United States

  • University of Washington, Advanced Cancer Research Group, Seattle, United States

  • New England Health Analytics LLC, Granby, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Bladder Cancer

  • Brain cancer

  • Solid malignancies

Biomarkers

  • Catalase

Drug/Treatment

  • rivaroxaban

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved